Stage III Non-small Cell Lung Cancer Clinical Trials

7 recruitingLast updated: June 17, 2026

There are 7 actively recruiting stage iii non-small cell lung cancer clinical trials across 7 countries. Studies span Phase 2, Not Applicable, Phase 1. Top locations include Aarhus, Denmark, Alicante, Alicante, Spain, Amsterdam, Netherlands. Updated daily from ClinicalTrials.gov.


Stage III Non-small Cell Lung Cancer Trials at a Glance

7 actively recruiting trials for stage iii non-small cell lung cancer are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Aarhus, Alicante, and Amsterdam. Lead sponsors running stage iii non-small cell lung cancer studies include Fundación GECP, Iovance Biotherapeutics, Inc., and Danish Lung Cancer Group.

Browse stage iii non-small cell lung cancer trials by phase

Treatments under study

About Stage III Non-small Cell Lung Cancer Clinical Trials

Looking for clinical trials for Stage III Non-small Cell Lung Cancer? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Stage III Non-small Cell Lung Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Stage III Non-small Cell Lung Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1Phase 2

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic MelanomaUnresectable MelanomaStage IV Non-Small Cell Lung Cancer+1 more
Iovance Biotherapeutics, Inc.53 enrolled11 locationsNCT05361174
Recruiting
Phase 2

IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)Unresectable Stage III Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China43 enrolled1 locationNCT07408635
Recruiting
Phase 2

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Locally AdvancedStage III Non-small Cell Lung CancerUnresectable
TheraOp110 enrolled11 locationsNCT06102057
Recruiting
Phase 2

PALACE: Cemiplimab Trial According to ctDNA Levels

Non-small Cell Lung Cancer MetastaticThoracic NeoplasmsStage IV Non-Small Cell Lung Cancer+3 more
Fundación GECP63 enrolled20 locationsNCT06917573
Recruiting
Not Applicable

The Beneficial Value of PET/CT in the Follow-up of Stage III Non-small Cell Lung Cancer Patients

Stage III Non-small Cell Lung Cancer
Radboud University Medical Center690 enrolled27 locationsNCT06082492
Recruiting
Phase 2

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Stage III Non-small Cell Lung Cancer
Sun Yat-sen University116 enrolled1 locationNCT05468242
Recruiting
Not Applicable

Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC

Radiotherapy Side EffectStage IV Non-Small Cell Lung CancerStage III Non-small Cell Lung Cancer
Danish Lung Cancer Group151 enrolled1 locationNCT03742687